Successful treatment of persistent pulmonary hypertension of the newborn with bosentan.
The sophisticated and expensive treatment modalities of persistent pulmonary hypertension of the newborn (PPHN), such as nitric oxide, are limited in developing countries. Alternative (less expensive) treatments are being sought and bosentan, an oral dual endothelin-1 receptor antagonist, may be an option for the treatment of PPHN. We report our experience of using bosentan in a neonate with severe PPHN.


CONCLUSIONS
Bosentan may be a useful adjuvant therapy in neonates with PPHN, providing significant improvement in oxygenation, and thus may be particularly useful in the treatment of PPHN in countries with limited resources.
Nakwan
N
N
Neonatal Intensive Care Units, Hat Yai Medical Education Center, Hat Yai Hospital, Songkhla, Thailand. nnakwan@hotmail.com
Choksuchat
D
D
Saksawad
R
R
Thammachote
P
P
Nakwan
N
N
D000959:Antihypertensive Agents / Q000627:therapeutic use*; D000077300:Bosentan; D003906:Developing Countries; D065128:Endothelin Receptor Antagonists; D006801:Humans; D006976:Hypertension, Pulmonary / Q000175:diagnosis / Q000188:drug therapy*; D007231:Infant, Newborn; D008297:Male; D012121:Respiration, Artificial; D013449:Sulfonamides / Q000627:therapeutic use*
D000959:Antihypertensive Agents; D065128:Endothelin Receptor Antagonists; D013449:Sulfonamides; D000077300:Bosentan